DNA polymerase ζ as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Shi, Ting Yan ^a,b,c   Yang, Li ^a,b   Yang, Gong ^a,b   Tu, Xiao Yu ^a,b   Wu, Xiaohua ^a,b   Cheng, Xi ^a,b   Wei, Qingyi ^a,d  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Cervical cancer; Chemoresistance; DNA repair; Pol ; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA POLYMERASE; DNA POLYMERASE XI; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG; DNA DIRECTED DNA POLYMERASE; DNA POLYMERASE ZETA; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DNA REPAIR; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; RADICAL HYSTERECTOMY; TUMOR INVASION; UTERINE CERVIX CARCINOMA; ADULT; BIOSYNTHESIS; CHEMORADIOTHERAPY; DRUG RESISTANCE; ENZYMOLOGY; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; UTERINE CERVIX TUMOR;

ADULT; CHEMORADIOTHERAPY; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84874368081     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0500-4     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Lissoni AA, Colombo N, Pellegrino A, et al. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian collaborative study. Ann Oncol. 2009;20:660-5.
3. Cadron I, Van Gorp T, Amant F, et al. Chemotherapy for recurrent cervical cancer. Gynecol Oncol. 2007;107:S113-8.
4. Burger H, Loos WJ, Eechoute K, et al. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 2011;14:22-34.
5. Friedberg EC. Suffering in silence: the tolerance of DNA damage. Nat Rev Mol Cell Biol. 2005;6:943-53.
6. Albertella MR, Lau A, O'Connor MJ. The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst). 2005;4:583-93.
7. Doles J, Oliver TG, Cameron ER, et al. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci USA. 2010;107:20786-91.
8. Lawrence CW, Hinkle DC. DNA polymerase zeta and the control of DNA damage induced mutagenesis in eukaryotes. Cancer Surv. 1996;28:21-31.
9. Wang H, Zhang SY, Wang S, et al. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. Neuro Oncol. 2009;11:790-802.
10. Cheng X, Cai SM, Li ZT, et al. Concurrent chemotherapy and adjuvant extended field irradiation after radical surgery for cervical cancer patients with lymph node metastases. Int J Gynecol Cancer. 2008;18:779-84.
11. Shi TY, Yang G, Tu XY, et al. RAD52 variants predict platinum resistance and prognosis of cervical cancer. PLoS ONE. 2012;7:e50461.
12. Cheng X, Yang G, Schmeler KM, et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011;121:323-7.
13. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol. 2009;27:4649-55.
14. Watanabe Y, Nakai H, Shimaoka M, et al. Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. Int J Clin Oncol. 2006;11:309-13.
15. Shao CJ, Fu J, Shi HL, et al. Activities of DNA-PK and Ku86, but not Ku70, may predict sensitivity to cisplatin in human gliomas. J Neurooncol. 2008;89:27-35.
16. Dunst J, Haensgen G. Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy. Strahlenther Onkol. 2001;177:635-40.
17. Yin M, Zhang H, Li H, et al. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. J Surg Oncol. 2012;105:206-11.
18. Nair DT, Johnson RE, Prakash L, et al. Rev1 employs a novel mechanism of DNA synthesis using a protein template. Science. 2005;309:2219-22.
19. Okada T, Sonoda E, Yoshimura M, et al. Multiple roles of vertebrate REV genes in DNA repair and recombination. Mol Cell Biol. 2005;25:6103-11.
20. Shachar S, Ziv O, Avkin S, et al. Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals. EMBO J. 2009;28:383-93.
21. Brondello JM, Pillaire MJ, Rodriguez C, et al. Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol zeta. Oncogene. 2008;27:6093-101.
22. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 2004;101:811-6.
23. Zhang S, Chen H, Zhao X, et al. REV3L 3'UTR 460 T > C polymorphism in microRNA target sites contributes to lung cancer susceptibility. Oncogene. 2012;. doi: 10.1038/onc.2012.32.